BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103 in treatment naïve nAMD patients BERKELEY HEIGHTS, N.J., July 20, 2026 (GLOBE
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July